<- All drugs

Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Bimagrumab

INVESTIGATIONAL

Activin type II receptor monoclonal antibody

graded results

ongoing records

effect domains

Evidence spread

High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Bimagrumab is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity and body composition; Intravenous infusion; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Bimagrumab INVESTIGATIONAL

body-composition Mixed

Moderate evidence

Foundational human readout for muscle preservation: in adults with T2D and overweight/obesity, bimagrumab MONOTHERAPY (no GLP-1RA) produced large fat-mass loss with a...

Heymsfield SB et al., JAMA Netw Open, 2021 Source

Full findingFoundational human readout for muscle preservation: in adults with T2D and overweight/obesity, bimagrumab MONOTHERAPY (no GLP-1RA) produced large fat-mass loss with a simultaneous GAIN in lean mass over 48 weeks, establishing that ActRII blockade is anabolic for muscle while reducing adiposity. This is lean-mass GAIN, distinct from the lean-PRESERVATION seen when such agents are added to incretins.

PopulationPhase-2 double-masked placebo-controlled RCT, N=75 randomised (58 completers), 48 weeks, IV q4w, adults with T2D, BMI 28-40; 9 US/UK sites.

Fundingindustry - Novartis (bimagrumab; disclosed)

Comparatorsplacebo